# The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study

Study · id `cardio:ct-nct02316821` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02316821](<https://clinicaltrials.gov/study/NCT02316821>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02316821

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

## Technical summary

Registry record NCT02316821. Randomized; double masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 216 participants (enrolled count; ClinicalTrials.gov record NCT02316821, source copy `cardio:ctgov-nct02316821-2017-10-27`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02316821, source copy `cardio:ctgov-nct02316821-2017-10-27`, retrieved 2026-10-26)
- Primary completion: 2016-05 (actual) (ClinicalTrials.gov record NCT02316821, source copy `cardio:ctgov-nct02316821-2017-10-27`, retrieved 2026-10-26)
- Completion: 2017-09 (actual) (ClinicalTrials.gov record NCT02316821, source copy `cardio:ctgov-nct02316821-2017-10-27`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02316821, source copy `cardio:ctgov-nct02316821-2017-10-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02316821-2017-10-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study
- Condition: Chronic Kidney Disease
- Condition: Type 2 Diabetes
- Intervention (Drug): RTA 402
- Intervention (Drug): Placebo
- Lead sponsor: Kyowa Kirin Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Kyowa Kirin Co., Ltd. (`cardio:org-kyowa-kirin-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study (`cardio:pubmed-37962746`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial (`cardio:pubmed-39294522`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8f71faececb148a6f1f8c42a0515615cd3ca3abf1144b670ac0fe83c9f5dd8af
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
